- The U.K.-based Oxford University researchers behind the COVID-19 treatment trial RECOVERY are back again, this time for a randomized controlled trial assessing SIGA Technologies Inc's SIGA smallpox treatment Tpoxx (tecovirimat) for monkeypox.
- The National Institute For Health and Care Research (NIHR) has commissioned and funded the study with a £3.7 million award. The first patients have now been recruited.
- The FDA approved tecovirimat in 2018 for smallpox in adults and children. The CDC has been using an expanded access program for monkeypox.
- Also Read: Experts Cast Doubt On Dependence On Monkeypox Vaccine Amid Limited Trial Data, Supply Crunch.
- And although the antiviral is only approved as a smallpox treatment, its FDA approval was based on studies in nonhuman primates infected with monkeypox.
- The trial of tecovirimat in non-hospitalized monkeypox patients will test the efficacy and safety of tecovirimat for monkeypox.
- The trial is looking to enroll about 500 participants. The trial will test 600 mg of tecovirimat twice daily for 14 days versus a placebo.
- Price Action: SIGA shares are down 4.80% at $21.21 on the last check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.